⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
CVKD News
Cadrenal Therapeutics, Inc. Common Stock
Form 8-K
sec.gov
CVKD
Form 8-K
sec.gov
CVKD
Cadrenal Therapeutics Announces up to $8.8 Million Private Placement Priced At-The-Market Under Nasdaq Rules
globenewswire.com
CVKD
Form 8-K
sec.gov
CVKD
Cadrenal Therapeutics Announces Selection of CAD-1005 Phase 2 Study for Late-Breaking Oral Presentation at ISTH 2026 Congress
globenewswire.com
CVKD
Form 8-K
sec.gov
CVKD
Cadrenal Therapeutics to File for FDA Rare Pediatric Disease Designation for Tecarfarin in Kawasaki Disease
globenewswire.com
CVKD
Cadrenal Therapeutics Advances Multi-Indication Strategy for CAD-1005; Launches Phase 2a Acute Kidney Injury (CSA-AKI) Clinical Plan to Accelerate Pharma Partnering at Upcoming BIO 2026
globenewswire.com
CVKD
Cadrenal Therapeutics to Showcase Phase 3-Ready CAD-1005 and Novel 12-LOX Platform at BIO International Convention 2026 Partnering Event
globenewswire.com
CVKD
Cadrenal Therapeutics to Participate in the Lytham Partners Spring 2026 Investor Conference on May 28, 2026
globenewswire.com
CVKD